Frank Behrens

7.4k citations

178 papers · 3.7k indexed · 3 hit papers · h-index 27

Impact in

Rheumatology top 0.2%
- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research

Papers in

Rheumatology 128
- Spondyloarthritis Studies and Treatments 97
- Rheumatoid Arthritis Research and Therapies 91
- Systemic Lupus Erythematosus Research 11
Hematology 67
- Autoimmune and Inflammatory Disorders Research 64

Co-authors: Philip J. Mease Dafna D. Gladman Peter Nash Diamant Thaçi Harald Burkhardt Kim Papp J. P. Kaltwasser Iain B. McInnes
Journals: Annals of the Rheumatic Diseases (47 papers)Lara D. Veeken (12 papers)RMD Open (9 papers)The Journal of Rheumatology (7 papers)Rheumatology and Therapy (7 papers)
Partner nations: Germany United States United Kingdom

In The Last Decade

Frank Behrens

164 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis 2022 · 134 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Annals of the Rheumatic Diseases
2021 New England Journal of Medicine
2017 New England Journal of Medicine

Peers

Countries citing papers authored by Frank Behrens

Since Specialization

Citations

This map shows the geographic impact of Frank Behrens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Behrens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Behrens more than expected).

Fields of papers citing papers by Frank Behrens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Behrens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Behrens. The network helps show where Frank Behrens may publish in the future.

Co-authors

The 25 scholars most cited alongside Frank Behrens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frank Behrens Line = papers co-authored together Frank Behrens links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Real-world sex differences in treatment persistence and reasons for discontinuation in psoriatic arthritis patients: results from the German RABBIT-SpA register Arthritis Research & Therapy ·Hussein A. Elsayed, Anja Weiß, Andreas Reich, Ly T. P. Trinh, Frank Behrens, Xenofon Baraliakos, Anne C. Regierer	2025	0
2	Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study Annals of the Rheumatic Diseases ·Peter C. Taylor, Philip J. Mease, Kurt de Vlam, Shephard Mpofu, A Hekker, Anne M. Stevens, Brian L. Wiens, Shakthidhar Vilvanathan, S. Ohlman, Joachim Feldwisch, Fredrik Y. Frejd, Nikolai C. Brun, Yun Ma, Edit Drescher, Eva Dokoupilová, Brendan Fox, D. Ross, Frank Behrens	2025	2
3	Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies RMD Open ·Laura C. Coates, Ricardo Blanco, Frank Behrens, Pawel Wityk, Filip Van den Bosch, Roberto Ranza, Yael Klionsky, Ahmed M. Soliman, Michael Chen, Derek Coombs, 石婷婷, N Motoya, 赵卿松, Ralph Lippe, Laure Gossec	2025	0
4	Efficacy of a cognitive-behavioral digital therapeutic on psychosocial outcomes in rheumatoid arthritis: randomized controlled trial SHILAP Revista de lepidopterología ·Linda T. Betz, Gitta Jacob, Johannes Knitza, 고금복, Frank Behrens	2024	4
5	Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial SKIN The Journal of Cutaneous Medicine ·Frank Behrens, Mauro Waldemar Keiserman, Kim Papp, Douglas White, M. Macia, 誠之吉村, 赵卿松, 森尾登, Ahmed M. Soliman, Wilda Devy Anjani, Lila Glotfelty	2024	0
6	A Phase 1b PK/PD Study to Demonstrate Antigen Elimination with RLYB212, A Monoclonal Anti-HPA-1a Antibody for FNAIT Prevention Thrombosis and Haemostasis ·Christof Geisen, Michael Grella, Maximillian Newman, Carmen Walter, Kudzai Kunaka, Jens Søndergaard Jensen, Douglas Sheridan, Kiran C. Patki, Róisín Armstrong, Bjøŕn Skogen, Frank Behrens, Erhard Seifried, Jens Kjeldsen‐Kragh, Mette Kjær, Michaela Köhm	2024	0
7	POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL Annals of the Rheumatic Diseases ·Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, Frank Behrens, Laure Gossec, M. Elaine Husni, Lars Erik Kristensen, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, Lloyd Ackert, Alice B. Gottlieb	2023	3
8	Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting The Journal of Rheumatology ·Beverly Ng, Deepak R. Jadon, Frank Behrens, Maarten de Wit, Oliver FitzGerald, Dafna D. Gladman, Philip J. Mease, D. C. O'SULLIVAN, Stephen R. Pennington, Georg Schett, Vinod Chandran, Kurt de Vlam	2023	1
9	An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study Journal of Thrombosis and Haemostasis ·Christof Geisen, Mette Kjær, Michael Grella, Bjøŕn Skogen, Róisín Armstrong, Frank Behrens, Zubin Bhagwagar, Kudzai Kunaka, Anette Mörtberg, 麻亜沙奥田, Maximillian Newman, Carmen Walter, Erhard Seifried, Agneta Wikman, Jens Kjeldsen‐Kragh, 고금복	2023	3
10	Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities RMD Open ·고금복, Frank Behrens	2023	3
11	Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA RMD Open ·Anne C. Regierer, Anja Weiß, Fabian Proft, Xenofon Baraliakos, Frank Behrens, Denis Poddubnyy, Georg Schett, Hanns‐Martin Lorenz, Feras Baba, Anja Strangfeld	2023	9
12	Charakterisierung von Patienten mit Psoriasisarthritis in der dermatologischen und rheumatologischen Versorgung: Analyse von zwei Registern JDDG Journal der Deutschen Dermatologischen Gesellschaft ·Matthias Augustin, Hussein A. Elsayed, Denys Azarov, Anja Weiß, Stephan Jeff Rustenbach, Brigitte Stephan, Martin Feuchtenberger, Ulrich Mrowietz, Diamant Thaçi, Petra Staubach, Xenofon Baraliakos, Anja Strangfeld, Ralph von Kiedrowski, Frank Behrens, Anne C. Regierer	2023	0
13	Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes Rheumatology and Therapy ·Eugen Feist, Xenofon Baraliakos, Frank Behrens, Diamant Thaçi, T. Klopsch, Syahrul Nur Rizky, Gonullu Demirag G, Klaus Pietzner, 真二青山, Peter‐Andreas Löschmann	2022	12
14	Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA) Journal of Clinical Medicine ·고금복, Ann Christina Foldenauer, D. Barnako, Rieke Alten, Martin Aringer, Marina Backhaus, Gerd R Burmester, Eugen Feist, Herbert Kellner, Klaus Krueger, Ulf Müller‐Ladner, Andrea Rubbert‐Roth, Hans‐Peter Tony, Siegfried Wassenberg, Harald Burkhardt, Frank Behrens	2022	1
15	OP0258 IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS – 16-WEEK RESULTS FROM A PHASE 2 STUDY Annals of the Rheumatic Diseases ·Frank Behrens, Jonathan Jameson, A Hekker, Kelly Kenneth, Олена Геннадіївна Варгуляк, Milica Kovačević Filipović, Надежда Олеговна Григорьева, Manika Daruka, D. Ross, Sultan Al Amro	2022	21
16	Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis Annals of the Rheumatic Diseases ·Philip J. Mease, Atul Deodhar, Désirée van der Heijde, Frank Behrens, Alan Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, Subhashis Banerjee Hit paper breakdown →	2022	134
17	AB0523 LONG-TERM SAFETY AND EFFECTIVENESS OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS AT 56 WEEKS FROM THE SELECT-PsA 1 STUDY Annals of the Rheumatic Diseases ·Iain B. McInnes, Koji Kato, Marina Magrey, 蒋成湘, Mitsumasa Kishimoto, (unknown), Derek Haaland, Alaa A Labeb, Yuanyuan Duan, Patrick Zueger, 付志风, Roger Lippé, Aileen L. Pangan, Frank Behrens	2021	4
18	Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial Annals of the Rheumatic Diseases ·Claudia Kedor, Joachim Listing, Jan Zernicke, Anja Weiß, Frank Behrens, Norbert Blank, Jörg Henes, Joern Kekow, Andrea Rubbert‐Roth, Hendrik Schulze‐Koops, Eva Seipelt, Christof Specker, Eugen Feist	2020	64
19	Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations Arthritis Care & Research ·Philip J. Mease, Dafna D. Gladman, Alexis Ogdie, Laura C. Coates, Frank Behrens, Arthur Kavanaugh, Iain B. McInnes, Rubén Queiró, B. Guérette, Michèle Brunori, Lichen Teng, Josef S Smolen	2020	7
20	Cytokines and inflammatory mediators [24-32] British journal of rheumatology ·Frank Behrens, Пенькова Ирина Витальевна, Toshiyuki Nayuki, Burkhard Möller, Heinfried H. Radeke, Ursula Fearon, Ronan Mullan, Robin Poole, Trevor Markham, Oliver FitzGerald, Barry Bresnihan, Douglas J. Veale	2005	1

About Frank Behrens

Frank Behrens is a scholar working on Rheumatology, Hematology, Immunology, Pathology and Forensic Medicine and Dermatology, having authored 178 papers that have together received 3.7k indexed citations. Recurring topics across this work include Spondyloarthritis Studies and Treatments (97 papers), Rheumatoid Arthritis Research and Therapies (91 papers), Psoriasis: Treatment and Pathogenesis (86 papers), Autoimmune and Inflammatory Disorders Research (64 papers), Systemic Lupus Erythematosus Research (11 papers), Chronic Lymphocytic Leukemia Research (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Dermatology and Skin Diseases (7 papers). The work is most often cited by research in Rheumatology (2.5k citations), Hematology (1.4k citations), Immunology (2.4k citations), Dermatology (464 citations) and Pathology and Forensic Medicine (272 citations). Frank Behrens has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Philip J. Mease, Dafna D. Gladman, Peter Nash, Diamant Thaçi, Harald Burkhardt, Kim Papp, J. P. Kaltwasser, Iain B. McInnes, Sujatha Menon and Keith S. Kanik. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken, RMD Open, The Journal of Rheumatology and Rheumatology and Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact